Normal view MARC view ISBD view

Outcomes of patients with unresected stage III and stage IV non small cell lung cancer: a single institution experience

In Lung India
Contributor(s): Chauhan N | Gaur D | Saini M | Rawat J | Sindhwani G | Jain N | Gupta M | Gupta M | Verma S K | Saini S | Lee HN | tiwanams@gmail.com | Tiwana MS.
Material type: materialTypeLabelArticleSeries: Vol 30 Issues 3.Publisher: 2013Description: 187-192.Subject(s): small cell lung cancer, overall survival, radiation therapy | Biologically equivalent dose, chemotherapy, non&#8209 | DDC classification: Online resources: Click here to access online In: Lung IndiaSummary: Introduction: To report on the demographic profile and survival outcomes of North Indian population affected with stage III and stage IV non‑small cell lung cancer (NSCLC). Materials and Methods: From November 2008 to January 2012, 138 consecutively diagnosed NSCLC patients were included in this study. The patient, tumor and treatment related factors were analyzed. Median overall survival (OS), Kaplan‑Meier survival plots, t‑test, Cox proportional hazards models were generated by multivariate analysis [MVA]) and analyzed on SPSS software (version 19.0; SPSS, Inc., Chicago, IL). Results: Median OS of stage III patients was 9.26 1.85 months and 2‑year survival rate of 13% while stage IV patients had median OS of 5 1.5 months with a 2‑year survival rate of 8%. Cox regression modeling for MVA demonstrated higher biologically equivalent dose (BED) (P 0.01) in stage III while in stage IV non‑squamous histology (P 
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
(Browse shelf) Available AR14388

Introduction: To report on the demographic profile and survival outcomes of North Indian population affected with stage III and stage IV non‑small cell lung cancer (NSCLC). Materials and Methods: From November 2008 to January 2012, 138 consecutively diagnosed NSCLC patients were included in this study. The patient, tumor and treatment related factors were analyzed. Median overall survival (OS), Kaplan‑Meier survival plots, t‑test, Cox proportional hazards models were generated by multivariate analysis [MVA]) and analyzed on SPSS software (version 19.0; SPSS, Inc., Chicago, IL).
Results: Median OS of stage III patients was 9.26 1.85 months and 2‑year survival rate of 13% while stage IV patients had median OS of 5 1.5 months with a 2‑year survival rate of 8%. Cox regression modeling for MVA demonstrated higher biologically equivalent dose (BED) (P 0.01) in stage III while in stage IV non‑squamous histology (P 

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha